No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Mark Baker?

Mr. Mark R. Baker

Chief Executive Officer

Progenics Pharmaceuticals , Inc.

Direct Phone: (646) ***-****       

Email: m***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Progenics Pharmaceuticals , Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

United States

Company Description

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer ... more

Find other employees at this company (155)

Background Information

Employment History

General Manager

Nova Scotia Junior Hockey League

Partner and Co-Chairman of the Capital Markets Group

Dewey Ballantine LLP

Software Engineer

Continental Corporation

Chief Business Officer

New York Water Taxi

Application Engineer

Jaguar Land Rover


Committee Member
The Allegiance Bowl Committee Inc

Admissions Advisor
Reading College


A.B. degree

History and Biochemistry

Columbia College


Columbia University School of Law

Web References (91 Total References)

Mark R. Baker ... [cached]

Mark R. Baker (4)

Mr. Baker, 61, Chief Executive Officer, joined the Company in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President - Corporate, in 2009 became President and a director, and has been CEO since March 2011. From 2003 to 2005, Mr. Baker was Chief Business Officer, Secretary and a director of New York Trans Harbor LLC, a privately-held ferry operation in New York City. From 1997 to 2001, he was Executive Vice President, Chief Legal Officer and Secretary of Continental Grain Company, a privately-held international agri-business and financial concern. Prior thereto, he was a partner and Co-Chairman of the Capital Markets Group of the New York law firm, Dewey Ballantine LLP. Mr. Baker also serves as Chairman of the board of directors of the Brooklyn Bridge Conservatory. He has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law. Mr. Baker's qualifications for serving as a director of the Company include his 30 years of business and legal experience, a significant portion of which has been in the life sciences industry. Mr. Baker has been involved in the senior management of the organizations with which he worked before joining the Company, and has extensive experience managing public and private companies, including specific experience with respect to the financial, accounting, audit, human resources, intellectual property, legal, environmental, insurance, scientific and operational aspects of businesses in diverse industries. He has also served as a legal and business advisor to numerous boards of directors of public and private entities.
02) Mark R. Baker

"We are excited to be moving ... [cached]

"We are excited to be moving our headquarters to this impressive, state-of-the-art building that truly reflects our vision as an innovative oncology company," stated Progenics CEO Mark Baker.

"We are excited to be moving ... [cached]

"We are excited to be moving our headquarters to this impressive, state-of-the-art building that truly reflects our vision as an innovative oncology company," stated Progenics CEO Mark Baker.

"EXINI's expertise in software design for ... [cached]

"EXINI's expertise in software design for imaging products will be invaluable as we develop our imaging toolkit for prostate cancer centered on our 1404 and PyL programs, and then more broadly as we seek to empower patients and the physicians with a suite of products designed to help guide treatment decisions," Progenics CEO Mark Baker said in a statement.

Progenics CEO Mark ... [cached]

Progenics CEO Mark Baker said: "This Breakthrough Therapy designation for Azedra reflects the urgent need for new options for patients suffering from pheochromocytoma and paraganglioma.

Similar Profiles

Other People with this Name

Other people with the name Baker

Wesley Baker
Babcock Design Group

Ruth Baker
Revels Tractor Co. Inc

Lee Baker

Russell Baker
Dalhousie Distict Golf Association

Tamara Baker
Aboriginal Employment Strategy Ltd

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory